Understanding the Implications of the 2014 IQ-CSRC Study on Assessing QT from Data Obtained in First–In-Human Studies


The definitive validation study results were announced at an FDA meeting in December 2014. The study creates a path for sponsors to successfully apply for waivers from stand-alone TQT studies and provides other benefits to sponsors. For complete information and White Paper download visit

Learn More

TQT Full Risk-Sharing Program

iCardiac Offers Industry-First TQT Full Risk-Sharing Program for Cardiac Safety Studies

Sponsors Are Guaranteed to Receive Precise, Conclusive Thorough QT (TQT) Results or Pay Nothing.

Tell me more:

Get more info on our services.
Find out how to become a partner.

Phone #:
Newsletter Signup: